President and Chief Executive Officer, CODA Biotherapeutics, Inc.
Mr. Narachi joined Ultragenyx as a board member in February 2015. Mr. Narachi currently serves as President, Chief Executive Officer, and a director of CODA Biotherapeutics, Inc., a private biotechnology company. He previously served as President, CEO and a director of Orexigen Therapeutics, Inc. from March 2009 to July 2018. Before that, Mr. Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., a leading therapeutics company, where he served as General Manager of Amgen’s Anemia Business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various senior positions throughout the organization over a 20-year career including: Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He served as General Manager of Amgen’s Anemia Business from 1999 to 2003 until his retirement in 2004. Mr. Narachi currently serves as chair of the Emerging Companies Section Governing Board of BIO, the Biotechnology Innovation Organization, and previously served as a member of the Board of Directors of PhRMA, the Pharmaceutical Research and Manufacturers of America. He also previously served as the chairman of the board of directors of Celladon Corporation and as a director of AMAG Pharmaceuticals, Inc. Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.